<DOC>
	<DOCNO>NCT02525107</DOCNO>
	<brief_summary>140 SCD patient [ 70 Hydroxyurea ] receive Omega-3 capsule whereas another 140 SCD patient [ 70 Hydroxyurea ] receive placebo recruit Sultan Qaboos University Hospital [ SQUH ] haematology specialty clinic . Patients randomize 1:1 ratio receive placebo Omega-3 52 week . The aim investigate therapeutic potential omega-3 fatty acid prevention vaso-occlusive crisis Omani patient sickle cell disease [ SCD ] .</brief_summary>
	<brief_title>Prevention Vaso-occlusive Painful Crisis Using Omega-3 Fatty Acid Supplements</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Moderate severe Sickle cell disease patient . Patients already receive Hydroxyurea [ HU ] eligible study . Patients able willing comply procedure study protocol . Acute episodes ( infection , vasoocclusive crisis ( VOC ) , acute chest syndrome ( ACS ) , stroke , priapism , splenic sequestration ) past one month enrolment . Previous stroke , comorbid disease like Essential Hypertension , Cardiomyopathy Heart failure , Diabetes , Chronic Renal Failure . Patients history adverse reaction omega3 fatty acid supplementation . Blood transfusion previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Prevention Vaso Occlusive Painful Crisis</keyword>
</DOC>